FDA Approves FoundationOne CDx as Companion Diagnostic for Alpelisib

The FDA approved FoundationOne CDx as a companion diagnostic for alpelisib in combination with fulvestrant for the treatment of men and postmenopausal women with HR+/HER2- PIK3CA-mutated breast cancer.

Source: CancerNetwork - December 5, 2019 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news